HomeAI · summaries
Storia in 3 fonti
Lilly oncology chief went from ‘extremely nervous’ to ‘blown away’ by new Jaypirca CLL data
In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to beat. | In patients with BTK-pretreated chronic lymphocytic leukemia, AbbVie and Roche’s Venclexta is the drug to beat. But no companies had taken a daunting head-to-head challenge—until Eli Lilly made the leap of faith with its Jaypirca.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
EHA: J&J sharpens myeloma edge as Talvey, Darzalex Faspro combo proves its worth in earlier disease stage
In a plenary session at the 2026 European Hematology Association (EHA) annual meeting in Stockholm, Johnson & Johnson brought to the world stage a reminder of its status as a…
- ·
endpoints.news
Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout
Eli Lilly made a push in blood cancer at this year’s European Hematology Association presenting data for Jaypirca as well as its first-ever clinical trial results in myelofibrosis.
- ·
Lilly oncology chief went from ‘extremely nervous’ to ‘blown away’ by new Jaypirca CLL data
In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to beat. | In patients with BTK-pretreated chronic…
- ·
benzinga.com
Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)
Eli Lilly's Phase 3 BRUIN CLL-322 study showed Jaypirca combination therapy cut progression or death risk by 45% in CLL/SLL.